Cullinan Therapeutics, Inc.
CGEMAs of the close on Sep 25, 2026
Price
$14.81
Market cap
$953M
P/E (diluted TTM)
—
Per-share earnings are not available for each of the last four quarters
EPS (TTM)
—
Per-share earnings are not available for each of the last four quarters
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Cullinan Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Cullinan Therapeutics, Inc. — 10-K filed Mar 9, 2023
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Qube Research & Technologies Ltd | 2026-03-31 | 90,316 | $1.28M | SEC filing |
| Tema ETFs LLC | 2026-03-31 | 62,421 | $887K | SEC filing |
| IEQ CAPITAL, LLC | 2026-03-31 | 27,736 | $394K | SEC filing |
| GSA CAPITAL PARTNERS LLP | 2026-03-31 | 43,339 | Not shown | SEC filing |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2026-03-31 | 67,656 | $961K | SEC filing |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2026-03-31 | 75,310 | $1.07M | SEC filing |
| True Wealth Design, LLC | 2026-03-31 | 54 | $768 | SEC filing |
| Nextech Invest, Ltd. | 2026-03-31 | 1,141,145 | $16.2M | SEC filing |
| Allworth Financial LP | 2026-03-31 | 1,146 | $16.3K | SEC filing |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2026-03-31 | 30,397 | $432K | SEC filing |
| EverSource Wealth Advisors, LLC | 2026-03-31 | 1,099 | $15.6K | SEC filing |
| TCG Crossover Management, LLC | 2026-03-31 | 406,786 | $5.78M | SEC filing |
| MERCER GLOBAL ADVISORS INC /ADV | 2026-03-31 | 14,109 | $200K | SEC filing |
| Knott David M Jr | 2026-03-31 | 24,200 | $344K | SEC filing |
| Point72 Asset Management, L.P. | 2026-03-31 | 905,376 | $12.9M | SEC filing |
| MAI Capital Management | 2026-03-31 | 938 | $13.3K | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 4,044 | $58K | SEC filing |
| TWIN FOCUS CAPITAL PARTNERS, LLC | 2026-03-31 | 595,489 | $8.46M | SEC filing |
| Sterling Capital Management LLC | 2026-03-31 | 1,799 | $25.6K | SEC filing |
| Ameritas Investment Partners, Inc. | 2026-03-31 | 4,305 | $61.2K | SEC filing |
- Each value is checked against Cullinan Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Cullinan Therapeutics, Inc.'s share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Cullinan Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-10-09 · Nichols Weston: Larger than all 10 other insider purchases of Common Stock on file. SEC filing
- 2024-05-06 · Michaelson Jennifer: Larger than 95 of the 101 other insider sales of Common Stock on file. SEC filing
- 2024-02-01 · Savill Corrine: Larger than 97 of the 101 other insider sales of Common Stock on file. SEC filing
- 2024-01-29 · Savill Corrine: Larger than 97 of the 101 other insider sales of Common Stock on file. SEC filing
- 2022-08-04 · Jovan-Embiricos Morana: Larger than 92 of the 101 other insider sales of Common Stock on file. SEC filing
- 2022-07-11 · Savill Corrine: Larger than 96 of the 101 other insider sales of Common Stock on file. SEC filing
- 2022-06-23 · Jovan-Embiricos Morana: Larger than 93 of the 101 other insider sales of Common Stock on file. SEC filing
- 2022-06-22 · Jovan-Embiricos Morana: Larger than 99 of the 101 other insider sales of Common Stock on file. SEC filing
- 2022-06-21 · Jovan-Embiricos Morana: Larger than 91 of the 101 other insider sales of Common Stock on file. SEC filing
- 2022-06-01 · BVF PARTNERS L P/IL: Larger than 9 of the 10 other insider purchases of Common Stock on file. SEC filing
- 2022-05-13 · Jovan-Embiricos Morana: Larger than 100 of the 101 other insider sales of Common Stock on file. SEC filing
- 2022-05-13 · Jovan-Embiricos Morana: Larger than 94 of the 101 other insider sales of Common Stock on file. SEC filing
- 2022-05-12 · Jovan-Embiricos Morana: Larger than all 101 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-05 | Michaelson Jennifer · Chief Scientific Officer | Common Stock | S — Open market or private sale | −7,800 | 14.60 | SEC filing |
| 2026-05-05 | Michaelson Jennifer · Chief Scientific Officer | Common Stock | S — Open market or private sale | −200 | 15.58 | SEC filing |
| 2026-03-05 | Michaelson Jennifer · Chief Scientific Officer | Common Stock | S — Open market or private sale | −8,000 | 15.68 | SEC filing |
| 2026-02-25 | Michaelson Jennifer · Chief Scientific Officer | Common Stock | S — Open market or private sale | −1,780 | 14.14 | SEC filing |
| 2026-02-24 | SUMER JACQUELYN L · Chief Legal Officer | Common Stock | S — Open market or private sale | −3,601 | 14.47 | SEC filing |
| 2026-02-24 | Michaelson Jennifer · Chief Scientific Officer | Common Stock | S — Open market or private sale | −3,601 | 14.47 | SEC filing |
| 2026-02-24 | Jones Jeffrey Alan · Chief Medical Officer | Common Stock | S — Open market or private sale | −4,582 | 14.47 | SEC filing |
| 2026-02-24 | AHMED NADIM · President and CEO | Common Stock | S — Open market or private sale | −13,515 | 14.47 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-16 | Meek David D. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +25,319 | SEC filing |
| 2026-06-16 | Doyle Mittie · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +21,781 | SEC filing |
| 2026-06-16 | Thistle Mary · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +25,319 | SEC filing |
| 2026-06-16 | Rosenberg Anthony · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +25,319 | SEC filing |
| 2026-06-16 | Allen Andrew R · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +21,781 | SEC filing |
| 2026-06-16 | Webster Stephen W · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +25,319 | SEC filing |
| 2026-05-05 | Michaelson Jennifer · Chief Scientific Officer | Common Stock | M — Exercise or conversion of derivative security | +4,000 | SEC filing |
| 2026-05-05 | Michaelson Jennifer · Chief Scientific Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −4,000 | SEC filing |
Showing 8 of 21 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2023-01-19 | BVF PARTNERS L P/IL · 10% owner | Common Stock | J — Other acquisition or disposition | −300,000 | SEC filing |
| 2023-01-19 | BVF PARTNERS L P/IL · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +30,000 | SEC filing |
| 2023-01-19 | BVF PARTNERS L P/IL · 10% owner | Common Stock | J — Other acquisition or disposition | −2,600,000 | SEC filing |
| 2023-01-19 | BVF PARTNERS L P/IL · 10% owner | Common Stock | J — Other acquisition or disposition | −3,500,000 | SEC filing |
| 2023-01-19 | BVF PARTNERS L P/IL · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +350,000 | SEC filing |
| 2023-01-19 | BVF PARTNERS L P/IL · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +260,000 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.